inclusion criteria: 1. 18 to 45 years old or at least 65 years old, 2. healthy adults or stable medical condition for adults with pre-existing medical conditions. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrolment, nor expected to require any significant change in therapy or hospitalization for worsening disease in foreseeable future. 3. group 1: healthy adults with no previous history of sars cov2 infection (pcr-, antigenic test- or chest tdm- or serology sars-cov-2-) group 2: healthy adults with history of infection with sars cov 2 (pcr+, antigenic test+ or chest tdm+ or serology sars-cov-2 of more than 5 months) or have been a household contact subject and have presented covid-19 symptoms \[experienced at least two of the following systemic symptoms: fever (≥ 38ºc), chills, myalgia, headache, sorethroat, new olfactory and taste disorder(s), gastrointestinal symptoms (diarrhea and/or vomiting) or at least one of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia\] since at least 5 months ago and have had a positive sars-cov-2 serology between this episode and pre-inclusion. 4. a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: * is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile. or * is of childbearing potential and agrees to use an effective contraceptive method from at least 4 weeks prior to vaccination until at least 4 weeks after the last vaccination. a participant of childbearing potential must have a negative blood pregnancy test at enrolment visit. 5. understands and agrees to comply with the study procedures (visits, phone calls) based on investigator judgement 6. written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the trial) (article l1122-1-1 of the public health code) 7. affiliated or beneficiary of a social security scheme (article l1121-11 of the public health code) (ame is not a social security scheme) 8. who agrees to be registered in the national file of persons who lend themselves to biomedical research (article l1121-16 of the public health code).

inclusion criteria: 1. 18 to 45 years old or at least 65 years old, 2. healthy adults or stable medical condition for adults with pre-existing medical conditions. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrolment, nor expected to require any significant change in therapy or hospitalization for worsening disease in foreseeable future. 3. group 1: healthy adults with no previous history of sars cov2 infection (pcr-, antigenic test- or chest tdm- or serology sars-cov-2-) group 2: healthy adults with history of infection with sars cov 2 (pcr+, antigenic test+ or chest tdm+ or serology sars-cov-2 of more than 5 months) or have been a household contact subject and have presented covid-19 symptoms \[experienced at least two of the following systemic symptoms: fever (≥ 38ºc), chills, myalgia, headache, sorethroat, new olfactory and taste disorder(s), gastrointestinal symptoms (diarrhea and/or vomiting) or at least one of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia\] since at least 5 months ago and have had a positive sars-cov-2 serology between this episode and pre-inclusion. 4. a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: * is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile. or * is of childbearing potential and agrees to use an effective contraceptive method from at least 4 weeks prior to vaccination until at least 4 weeks after the last vaccination. a participant of childbearing potential must have a negative blood pregnancy test at enrolment visit. 5. understands and agrees to comply with the study procedures (visits, phone calls) based on investigator judgement 6. written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the trial) (article l1122-1-1 of the public health code) 7. affiliated or beneficiary of a social security scheme (article l1121-11 of the public health code) (ame is not a social security scheme) 8. who agrees to be registered in the national file of persons who lend themselves to biomedical research (article l1121-16 of the public health code).

inclusion criteria: 18 to 45 years old or at least 65 years old, healthy adults or stable medical condition for adults with pre-existing medical conditions. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrolment, nor expected to require any significant change in therapy or hospitalization for worsening disease in foreseeable future. group 1: healthy adults with no previous history of sars cov2 infection (pcr-, antigenic test- or chest tdm- or serology sars-cov-2-) group 2: healthy adults with history of infection with sars cov 2 (pcr+, antigenic test+ or chest tdm+ or serology sars-cov-2 of more than 5 months) or have been a household contact subject and have presented covid-19 symptoms [experienced at least two of the following systemic symptoms: fever (≥ 38ºc), chills, myalgia, headache, sorethroat, new olfactory and taste disorder(s), gastrointestinal symptoms (diarrhea and/or vomiting) or at least one of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia] since at least 5 months ago and have had a positive sars-cov-2 serology between this episode and pre-inclusion. a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile. or is of childbearing potential and agrees to use an effective contraceptive method from at least 4 weeks prior to vaccination until at least 4 weeks after the last vaccination. a participant of childbearing potential must have a negative blood pregnancy test at enrolment visit. understands and agrees to comply with the study procedures (visits, phone calls) based on investigator judgement written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the trial) (article l1122-1-1 of the public health code) affiliated or beneficiary of a social security scheme (article l1121-11 of the public health code) (ame is not a social security scheme) who agrees to be registered in the national file of persons who lend themselves to biomedical research (article l1121-16 of the public health code).

inclusion criteria: 18 to 45 years old or at least 65 years old, healthy adults or stable medical condition for adults with pre-existing medical conditions. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrolment, nor expected to require any significant change in therapy or hospitalization for worsening disease in foreseeable future. group 1: healthy adults with no previous history of sars cov2 infection (pcr-, antigenic test- or chest tdm- or serology sars-cov-2-) group 2: healthy adults with history of infection with sars cov 2 (pcr+, antigenic test+ or chest tdm+ or serology sars-cov-2 of more than 5 months) or have been a household contact subject and have presented covid-19 symptoms [experienced at least two of the following systemic symptoms: fever (≥ 38ºc), chills, myalgia, headache, sorethroat, new olfactory and taste disorder(s), gastrointestinal symptoms (diarrhea and/or vomiting) or at least one of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia] since at least 5 months ago and have had a positive sars-cov-2 serology between this episode and pre-inclusion. a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile. or is of childbearing potential and agrees to use an effective contraceptive method from at least 4 weeks prior to vaccination until at least 4 weeks after the last vaccination. a participant of childbearing potential must have a negative blood pregnancy test at enrolment visit. understands and agrees to comply with the study procedures (visits, phone calls) based on investigator judgement written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the trial) (article l1122-1-1 of the public health code) affiliated or beneficiary of a social security scheme (article l1121-11 of the public health code) (ame is not a social security scheme) who agrees to be registered in the national file of persons who lend themselves to biomedical research (article l1121-16 of the public health code).

inclusion criteria: 1. 18 to 45 years old or at least 65 years old, 2. healthy adults or stable medical condition for adults with pre-existing medical conditions. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrolment, nor expected to require any significant change in therapy or hospitalization for worsening disease in foreseeable future. 3. group 1: healthy adults with no previous history of sars cov2 infection (pcr-, antigenic test- or chest tdm- or serology sars-cov-2-) group 2: healthy adults with history of infection with sars cov 2 (pcr+, antigenic test+ or chest tdm+ or serology sars-cov-2 of more than 5 months) or have been a household contact subject and have presented covid-19 symptoms [experienced at least two of the following systemic symptoms: fever (≥ 38ºc), chills, myalgia, headache, sorethroat, new olfactory and taste disorder(s), gastrointestinal symptoms (diarrhea and/or vomiting) or at least one of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia] since at least 5 months ago and have had a positive sars-cov-2 serology between this episode and pre-inclusion. 4. a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: - is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile. or - is of childbearing potential and agrees to use an effective contraceptive method from at least 4 weeks prior to vaccination until at least 4 weeks after the last vaccination. a participant of childbearing potential must have a negative blood pregnancy test at enrolment visit. 5. understands and agrees to comply with the study procedures (visits, phone calls) based on investigator judgement 6. written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the trial) (article l1122-1-1 of the public health code) 7. affiliated or beneficiary of a social security scheme (article l1121-11 of the public health code) (ame is not a social security scheme) 8. who agrees to be registered in the national file of persons who lend themselves to biomedical research (article l1121-16 of the public health code).

inclusion criteria: 1. 18 to 45 years old or at least 65 years old, 2. healthy adults or stable medical condition for adults with pre-existing medical conditions. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrolment, nor expected to require any significant change in therapy or hospitalization for worsening disease in foreseeable future. 3. group 1: healthy adults with no previous history of sars cov2 infection (pcr-, antigenic test- or chest tdm- or serology sars-cov-2-) group 2: healthy adults with history of infection with sars cov 2 (pcr+, antigenic test+ or chest tdm+ or serology sars-cov-2 of more than 5 months) or have been a household contact subject and have presented covid-19 symptoms [experienced at least two of the following systemic symptoms: fever (≥ 38ºc), chills, myalgia, headache, sorethroat, new olfactory and taste disorder(s), gastrointestinal symptoms (diarrhea and/or vomiting) or at least one of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia] since at least 5 months ago and have had a positive sars-cov-2 serology between this episode and pre-inclusion. 4. a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: - is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile. or - is of childbearing potential and agrees to use an effective contraceptive method from at least 4 weeks prior to vaccination until at least 4 weeks after the last vaccination. a participant of childbearing potential must have a negative blood pregnancy test at enrolment visit. 5. understands and agrees to comply with the study procedures (visits, phone calls) based on investigator judgement 6. written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the trial) (article l1122-1-1 of the public health code) 7. affiliated or beneficiary of a social security scheme (article l1121-11 of the public health code) (ame is not a social security scheme) 8. who agrees to be registered in the national file of persons who lend themselves to biomedical research (article l1121-16 of the public health code).

inclusion criteria: 1. 18 to 45 years old or at least 65 years old, 2. healthy adults or stable medical condition for adults with pre-existing medical conditions. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrolment, nor expected to require any significant change in therapy or hospitalization for worsening disease in foreseeable future. 3. group 1: healthy adults with no previous history of sars cov2 infection (pcr-, antigenic test- or chest tdm- or serology sars-cov-2-) group 2: healthy adults with history of infection with sars cov 2 (pcr+, antigenic test+ or chest tdm+ or serology sars-cov-2+ of more than 6 months) 4. a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: - is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile. or - is of childbearing potential and agrees to use an effective contraceptive method from at least 4 weeks prior to vaccination until at least 4 weeks after the last vaccination. a participant of childbearing potential must have a negative blood pregnancy test at enrolment visit. 5. understands and agrees to comply with the study procedures (visits, phone calls) based on investigator judgement 6. written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the trial) (article l1122-1-1 of the public health code) 7. affiliated or beneficiary of a social security scheme (article l1121-11 of the public health code) (ame is not a social security scheme) 8. who agrees to be registered in the national file of persons who lend themselves to biomedical research (article l1121-16 of the public health code).

inclusion criteria: 1. 18 to 45 years old or at least 65 years old, 2. healthy adults or stable medical condition for adults with pre-existing medical conditions. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrolment, nor expected to require any significant change in therapy or hospitalization for worsening disease in foreseeable future. 3. group 1: healthy adults with no previous history of sars cov2 infection (pcr-, antigenic test- or chest tdm- or serology sars-cov-2-) group 2: healthy adults with history of infection with sars cov 2 (pcr+, antigenic test+ or chest tdm+ or serology sars-cov-2+ of more than 6 months) 4. a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: - is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile. or - is of childbearing potential and agrees to use an effective contraceptive method from at least 4 weeks prior to vaccination until at least 4 weeks after the last vaccination. a participant of childbearing potential must have a negative blood pregnancy test at enrolment visit. 5. understands and agrees to comply with the study procedures (visits, phone calls) based on investigator judgement 6. written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the trial) (article l1122-1-1 of the public health code) 7. affiliated or beneficiary of a social security scheme (article l1121-11 of the public health code) (ame is not a social security scheme) 8. who agrees to be registered in the national file of persons who lend themselves to biomedical research (article l1121-16 of the public health code).